224 related articles for article (PubMed ID: 26794891)
1. Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.
Yokoyama S; Miyoshi H; Nishi T; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Kakuma T; Ohshima K
Ann Thorac Surg; 2016 Apr; 101(4):1361-9. PubMed ID: 26794891
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.
Hakiri S; Fukui T; Mori S; Kawaguchi K; Nakamura S; Ozeki N; Kato T; Goto M; Yatabe Y; Yokoi K
Ann Thorac Surg; 2019 Feb; 107(2):418-424. PubMed ID: 30312607
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
4. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
[TBL] [Abstract][Full Text] [Related]
6. Long-term disease-free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression.
Mineo TC; Ambrogi V; Mineo D; Baldi A
Cancer; 2005 Nov; 104(10):2063-71. PubMed ID: 16206298
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
[TBL] [Abstract][Full Text] [Related]
9. Thymoma: prognostic factors and treatment outcomes.
Gripp S; Hilgers K; Wurm R; Schmitt G
Cancer; 1998 Oct; 83(8):1495-503. PubMed ID: 9781943
[TBL] [Abstract][Full Text] [Related]
10. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
11. Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome.
Tateyama H; Sugiura H; Yamatani C; Yano M
Hum Pathol; 2011 Apr; 42(4):533-40. PubMed ID: 21237498
[TBL] [Abstract][Full Text] [Related]
12. Thymoma: inter-relationships among World Health Organization histology, Masaoka staging and myasthenia gravis and their independent prognostic significance: a single-centre experience.
Ruffini E; Filosso PL; Mossetti C; Bruna MC; Novero D; Lista P; Casadio C; Oliaro A
Eur J Cardiothorac Surg; 2011 Jul; 40(1):146-53. PubMed ID: 21093283
[TBL] [Abstract][Full Text] [Related]
13. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
15. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
16. The major prognostic factors of thymomas: about a Tunisian study of 100 cases.
Mlika M; Boudaya MS; Laabidi S; Zaimi Y; Smadhi H; Marghli A; El Mezni F; Kilani T
Pathologica; 2015 Mar; 107(1):9-13. PubMed ID: 26591625
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
18. Survival after extended thymectomy for thymoma.
Sakamoto M; Murakawa T; Konoeda C; Inoue Y; Kitano K; Sano A; Fukayama M; Nakajima J
Eur J Cardiothorac Surg; 2012 Mar; 41(3):623-7. PubMed ID: 22011779
[TBL] [Abstract][Full Text] [Related]
19. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
